Richard Chen, PA
Staff Affiliate in Emergency Medicine
Research & Publications
Biography
News
Coauthors
Selected Publications
- Prevalence and dynamics of circulating tumor DNA (ctDNA) among patients (pts) with HER2+ breast cancer (BC) receiving neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) in the DAPHNe trial.Waks A, Tarantino P, Li T, Ogayo E, Rahman T, DiLullo M, El-Refai S, Abbott C, Boyle S, Chen R, Desai N, Spring L, Tung N, King T, Krop I, Tayob N, Mittendorf E, Tolaney S, Winer E, Parsons H. Prevalence and dynamics of circulating tumor DNA (ctDNA) among patients (pts) with HER2+ breast cancer (BC) receiving neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) in the DAPHNe trial. Journal Of Clinical Oncology 2024, 42: 588-588. DOI: 10.1200/jco.2024.42.16_suppl.588.
- Circulating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay.Solar Vasconcelos J, Titmuss E, Navarro F, Abbott C, Chia B, Topham J, Ladua G, Krishnan T, Hegebarth D, Lim H, Gill K, Gill S, Brown C, Ghuman A, Meneghetti A, Renouf D, Schaeffer D, Chen R, Boyle S, Loree J. Circulating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay. Journal Of Clinical Oncology 2024, 42: e15625-e15625. DOI: 10.1200/jco.2024.42.16_suppl.e15625.
- Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer.Garcia-Murillas I, Cutts R, Abbott C, Boyle S, Pugh J, Chen R, Dunne K, Bunce C, Johnston S, Ring A, Russell S, Evans A, Skene A, Wheatley D, Smith I, Turner N. Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer. Journal Of Clinical Oncology 2024, 42: 1010-1010. DOI: 10.1200/jco.2024.42.16_suppl.1010.
- Prognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors in the context of phase 1 clinical trials.Toledo R, Calahorro García A, Mirallas O, Moreno A, Galvao V, Alonso G, Vieito M, Brana I, Oberoi A, Lostes-Bardaji M, Jimenez J, Sanz M, Viaplana C, Perez-Lopez R, Nuciforo P, Abbott C, Pugh J, Chen R, Boyle S, Garralda E. Prognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors in the context of phase 1 clinical trials. Journal Of Clinical Oncology 2024, 42: 2510-2510. DOI: 10.1200/jco.2024.42.16_suppl.2510.
- An algorithm to identify patients aged 0–3 with rare genetic disordersWebb B, Lau L, Tsevdos D, Shewcraft R, Corrigan D, Shi L, Lee S, Tyler J, Li S, Wang Z, Stolovitzky G, Edelmann L, Chen R, Schadt E, Li L. An algorithm to identify patients aged 0–3 with rare genetic disorders. Orphanet Journal Of Rare Diseases 2024, 19: 183. PMID: 38698482, PMCID: PMC11064409, DOI: 10.1186/s13023-024-03188-9.
- Abstract 6094: Detection of MRD assessment with the Personalis NeXT Personal assay using MATRIX plasma-in-plasma contrived samplesLabrousse P, Russell H, Hamid S, Bartha G, Lyle J, Norton D, Northcott J, Boyle S, Chen R, Stetson D, Hadfield J. Abstract 6094: Detection of MRD assessment with the Personalis NeXT Personal assay using MATRIX plasma-in-plasma contrived samples. Cancer Research 2024, 84: 6094-6094. DOI: 10.1158/1538-7445.am2024-6094.
- Abstract 5034: Analytic validation of an ultra-sensitive tumor-informed circulating tumor DNA assay based on whole genome sequencingNorthcott J, Bartha G, Harris J, Ma S, Hong M, Zhang Q, Chen R, Lyle J. Abstract 5034: Analytic validation of an ultra-sensitive tumor-informed circulating tumor DNA assay based on whole genome sequencing. Cancer Research 2024, 84: 5034-5034. DOI: 10.1158/1538-7445.am2024-5034.
- Abstract 976: Detection of circulating tumor DNA predicts survival in advanced HCC patients treated with personalized therapeutic DNA cancer vaccine in combination with immune checkpoint blockadeYan J, Li B, Northcott J, Abbott C, Pyke R, Perales-Linares R, Cooch N, Rochestie S, Peters J, Gane E, Yarchoan M, Marron T, Boyle S, Csiki I, Chen R, Sardesai N. Abstract 976: Detection of circulating tumor DNA predicts survival in advanced HCC patients treated with personalized therapeutic DNA cancer vaccine in combination with immune checkpoint blockade. Cancer Research 2024, 84: 976-976. DOI: 10.1158/1538-7445.am2024-976.
- LBA55 An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancerBlack J, Frankell A, Veeriah S, Colopi M, Hill M, Abbott C, Boyle S, Li B, Chen R, Bakir M, Ruiz C, Huebner A, Jamal-Hanjani M, McGranahan N, Swanton C. LBA55 An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer. Annals Of Oncology 2023, 34: s1294. DOI: 10.1016/j.annonc.2023.10.049.